Paxlovid 5 days

Phase 2Small molecule

AANRS, Emerging Infectious Diseases

Paxlovid 5 days is one of 19 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

Activella

Eli Lilly

Preclinical

—3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

Rayaldee

OOrganon and Co

Preclinical

1 6

SARS-COV-2 VACCINE

Moderna

Preclinical

2 7

Paxlovid 5 days

AANRS, Emerging Infectious Diseases

Phase 2

2 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

COVID-19

NCT05587894

Clinical

Trials by Indication[1]

COVID-192 trials

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

Recruiting·CCalmy Alexandra·Phase 2·NCT07406217·256 enrolled

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

Recruiting·AANRS, Emerging Infectious Diseases·Phase 2·NCT05587894·256 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Paxlovid 5 days. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paxlovid 5 days compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paxlovid 5 days. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ANRS, Emerging Infectious Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AANRS, Emerging Infectious Diseases

Paxlovid 5 days

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

COVID-192 trials

References

Drug Info

Quick Facts

Related News